BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 29382307)

  • 1. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
    Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
    BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
    Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
    Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
    Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A
    Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
    Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
    PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
    Pernot J; Puzenat E; Magy-Bertrand N; Manzoni P; Gondouin A; Bourdin H; Simon-Rigaud ML; Regnard J; Degano B
    Respiration; 2012; 84(6):461-8. PubMed ID: 22301769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
    Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease.
    Takei R; Arita M; Kumagai S; Ito Y; Tokioka F; Koyama T; Saito R; Nishimura K; Tokumasu H; Ishida T
    Respirology; 2018 Apr; 23(4):385-391. PubMed ID: 28925574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis.
    Foeldvari I; Klotsche J; Hinrichs B; Helmus N; Kasapcopur O; Adrovic A; Sztajnbok F; Terreri MT; Anton J; Smith V; Katsicas M; Kostik M; Vasquez-Canizares N; Avcin T; Feldman B; Janarthanan M; Santos MJ; Sawhney S; Schonenberg-Meinema D; Sifuentes-Giraldo WA; Alexeeva E; Appenzeller S; Battagliotti C; Berntson L; Bica B; Costa-Reis P; Eleftheriou D; Kallinich T; Lehman T; Marrani E; Minden K; Nielsen S; Nuruzzaman F; Patwardhan A; Khubchandani R; Stanevicha V; Uziel Y; Torok KS
    Arthritis Care Res (Hoboken); 2022 Mar; 74(3):364-370. PubMed ID: 33141441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality.
    Champtiaux N; Cottin V; Chassagnon G; Chaigne B; Valeyre D; Nunes H; Hachulla E; Launay D; Crestani B; Cazalets C; Jego P; Bussone G; Bérezné A; Guillevin L; Revel MP; Cordier JF; Mouthon L;
    Semin Arthritis Rheum; 2019 Aug; 49(1):98-104. PubMed ID: 30409416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
    Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
    PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
    Fischer A; Swigris JJ; Bolster MB; Chung L; Csuka ME; Domsic R; Frech T; Hinchcliff M; Hsu V; Hummers LK; Gomberg-Maitland M; Mathai SC; Simms R; Steen VD
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-109-14. PubMed ID: 25372796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
    Nawata T; Shirai Y; Suzuki M; Kuwana M
    Rheumatology (Oxford); 2021 Jan; 60(1):250-255. PubMed ID: 32699895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
    Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
    Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
    Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.